Minutes - Medication WG 2022-06-21
From Health Level 7 Belgium Wiki
Revision as of 09:24, 21 June 2022 by KarlienErauw (talk | contribs) (Created page with "===== '''Attendees''' ===== * Annemieke Vergauwe * Bart Decuypere * Jean-Michel Polfliet * Jens Penny * José Costa Teixeira * Karlien Erauw * Pablo Christiaens * Tom He...")
Attendees
- Annemieke Vergauwe
- Bart Decuypere
- Jean-Michel Polfliet
- Jens Penny
- José Costa Teixeira
- Karlien Erauw
- Pablo Christiaens
- Tom Henkens
Excused/Not present
- Anne Nerenhausen
- Bruno Casneuf
- Dieter Sauvillers
- Elhassan Baazizi
- Hanne Vuegen
- Jan Lenie
- Jean-Louis Maggetto
- Katrien Thorré
- Lars Vanreppelen
- Marc Buckens
- Nick Hermans
- Nils Devos
- Richard Francken
- Thomas Van Langendonck
- Tom De Backer
- Walter Bollaert
- Will van Norel
Agenda
- Future of medication scheme
Minutes
- Work on business rules is still ongoing at RIZIV end
- before we said that it has to be part of the implementation guide
- however, can we go and publish the medication scheme ?
- goal is for prescribor applications to start using the medication treatment
- We need some documentation for the migration from Kmehr to FHIR: input is needed
- We have to complexities of contraindications and (drug) allergies & intolerances
- drug allergies & intolerances are related to decision support, therefore might not be needed to include in the medication scheme but offer as additional service
- modelling of contraindications needs still to be determined, which can also be temporarily (f.e. pregnancy, breastfeeding)
- allergy & intolerance will be the way to present this kind of info
- there are 2 types for which distinction need to be made: patient related & drug related
- patient's condition is part of medical history (f.e. epilepsy)
- SAM viewer, there is VNP, CNK etc
- how many tables are there in the database ?
- this is the hierarchy: vmp-group > AMP > AMPP > CNK (old)
- concepts to be uses in MS will have to be defined
- f.e. support substances ?
- Jens will have a look
Agenda items for next meeting
- Current state of profiles on medication view and treatment lines and how it all works at operational level
- Review made changes
- Collect feedback on contraindications
- Identifying business rules
Next meeting July 5 at 11AM